Fatty Liver Disease May Reach 1.8 Billion by 2050

Nearly 1.8 billion people could be living with fatty liver disease by 2050, Earth.com reported, citing new figures from the Institute for Health Metrics and Evaluation at the University of Washington. The count stood at about 1.3 billion in 2023, roughly one in six people, spread across 204 countries and territories. Cases have risen from about 500 million in 1990. The study reported the 2050 projection as the next stage of a climb already under way, not a break from it.

Doctors now call the condition MASLD, short for metabolic dysfunction-associated steatotic liver disease, a name chosen to mark that the liver fat is driven by metabolism rather than alcohol. Sustained high blood sugar blunts the work of insulin, and the liver keeps storing the excess energy as fat. Extra body fat adds to the strain, the study reported, as enlarged fat cells release inflammatory signals that keep the liver under pressure. Left to run, the fat can harden into the scarring known as cirrhosis, and in some patients into liver cancer.

A quiet condition with a long fuse

MASLD carries few signs in its early years. For a long stretch it stays silent, the study reported, which is why MASLD reads as a hidden burden. Patients tend to learn of fatty liver disease by accident, on a blood test or a scan ordered for something else. Where symptoms do show, as tiredness or an ache below the right ribs, they are easy to wave off. That silence puts the weight on screening, and it is the reason preventive checks travel well, because a patient can book a metabolic workup abroad long before any symptom would prompt one at home. Thailand has built part of its healthspan and longevity offer on that logic, selling early testing to visitors who feel well.

The 2023 data split along clear lines. Men carried higher rates than women, the study reported, with cases among men peaking between the ages of 35 and 39. Among women the peak fell later, between 55 and 59, at the point where metabolic risk tends to gather. That age gap matters because more years spent with liver fat means more time for the damage to set, and less chance of turning it back.

Where the burden falls

North Africa and the Middle East reported the highest rate in 2023, about 29,246 cases per 100,000 people, Earth.com reported. High-income Asia Pacific reported the lowest, which tells against any simple reading that wealth alone decides the outcome. Countries with thinner healthcare provision carried a heavier load of illness even where their raw case rates were not the highest. The study tied the pattern to diet, the quality of diabetes care and how far screening reaches.

The rise in serious cases has so far run behind the rise in total cases. Better treatment keeps patients alive longer after cirrhosis or cancer sets in, which holds down the measured rate of severe disease for now. The large stock of early disease also sits in the records before complications have had time to surface. The study read the lag as a warning, not a reprieve. A much larger wave of advanced MASLD, costly to treat, could arrive over the coming decades. Advanced MASLD means cirrhosis and, in some patients, liver cancer.

The drivers, and what they change

High blood sugar was the single biggest contributor to the MASLD burden, the study reported, followed by a raised body mass index and then smoking. That is metabolic dysfunction-associated steatotic liver disease driven by metabolism, not by alcohol. That ranking ties liver health to everyday metabolic health and pulls it away from the old association with alcohol. Managing blood sugar, weight and smoking early could hold down future MASLD cases before any liver injury shows on a scan. Lifestyle change stays central to early care, the study reported, as weight loss lowers liver fat and inflammation and physical activity pulls sugar from the blood and eases the load on insulin.

The catch is access. Those measures depend on affordable food, time to exercise and steady follow-up, none of them evenly spread. The study noted that its projections could shift as data from lower-resource settings improve, but it held that the direction was not in doubt. The Global Burden of Disease 2023 MASLD Collaborators said the findings offer “an evidence base for policy makers to set specific targets” and a case for folding MASLD into wider metabolic and liver disease plans.

For medical travel the reading is plain. Demand of this kind is a symptom of gaps at home, in MASLD screening and in metabolic care, and it favours destinations that can offer the diagnostics and the follow-through. The same shift toward earlier, testing-led care runs through the wider move that longevity tourism represents, where the sale is prevention rather than repair.

What to watch

The near-term test is whether case counts and severe-disease rates start to converge as the early stock of MASLD ages. Destinations pitching metabolic and liver screening will show in their volumes whether the preventive message is landing with patients who still feel well. The figure to track is the count of about 1.3 billion in 2023. Whether the next global estimate moves it toward the 1.8 billion projected for 2050 will show if the climb is bending.